Turkish Study Finds IMRT Beats Conformal Radiotherapy for Pleural Mesothelioma Treatment, According to Surviving Mesothelioma
Raleigh, NC (PRWEB) May 10, 2017 -- Scientists in Ankara, Turkey say their evaluation of pleural mesothelioma patients who had either intensity-modulated radiotherapy or a more conventional approach suggests that IMRT may be the better option. Surviving Mesothelioma has just posted an article on the new research. Click here to read it now.
The Gazi University study analyzed the cases of 12 mesothelioma patients who received one-side radiation for pleural mesothelioma in doses ranging from 1.8 Gy to 50.4 Gy.
“Intensity-modulated radiation therapy was statistically superior in target coverage and dose homogeneity,” says Sukran Ulger, MD, a radiation oncologist and part of the medical faculty at Gazi University.
According to the study in the journal Technology in Cancer Research and Treatment, with IMRT, mesothelioma tumors received a higher dose of cancer-killing radiation while the surrounding healthy lung tissue received less.
“Given that radiotherapy is often part of the multi-modal treatment of pleural mesothelioma, this study may sway patients and families to seek out cancer centers where IMRT is an option,” says Alex Strauss, Managing Editor for Surviving Mesothelioma.
For a better understanding of IMRT in mesothelioma treatment and all the details of the new study, see Targeted Radiotherapy for Pleural Mesothelioma, now available on the Surviving Mesothelioma website.
Ulger, S, et al, “Intensity-Modulated Radiation Therapy Improves the Target Coverage Over 3-D Planning While Meeting Lung Tolerance Doses for All Patients With Malignant Pleural Mesothelioma”, June 2017, Technology in Cancer Research & Treatment, pp. 332-338, http://journals.sagepub.com/doi/abs/10.1177/1533034616678110
For more than a decade, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.
Michael Ellis, Cancer Monthy, http://www.survivingmesothelioma.com, +1 (919) 570-8595, [email protected]
Share this article